How a 30-person ibogaine study moved through veteran philanthropy, Stanford, Silicon Valley biotech and US state legislatures — and why the money is only part of the story.

In January 2024, Nature Medicine published an unusual study involving 30 former US Special Operations Forces veterans with histories of traumatic brain injury. They had travelled to Mexico for treatment with ibogaine, an intense and medically risky psychedelic unavailable for treatment in the United States. Stanford researchers assessed them before treatment, immediately afterwards and again one month later.

The results were remarkable enough to travel far beyond the journal.

Fifteen participants met criteria for major depressive disorder at baseline, 14 for an anxiety disorder and 23 for PTSD. One month after treatment, effect sizes on clinician-rated PTSD, depression and anxiety measures were all above 2.0. An exploratory analysis found that the proportion registering suicidal ideation on one depression-scale item fell from 47% at baseline to zero immediately after treatment and 7% one month later.

Eighteen months later, Texas had enacted legislation around an unprecedented $50 million state commitment to ibogaine drug development. During debate in the Texas House, legislators explicitly invoked the Stanford study and described its veterans, remission rates and extraordinary apparent improvements. Arizona subsequently appropriated $5 million for clinical ibogaine research, conditional on at least another $5 million being raised privately; on 5 August 2026, Barrow Neurological Institute announced that it had received the state grant for a Phase 1/2 trial in traumatic brain injury.

That is a remarkable journey for a scientific finding.

But following it backwards reveals something more interesting than a straightforward story of promising research convincing policymakers.

The Stanford study emerged from an ecosystem in which veteran advocates, treatment providers, billionaire philanthropists, academics, patent holders and later biotechnology investors repeatedly overlap. The same philanthropic families appear at different points in the chain. Researchers who produced the academic evidence became connected to a company developing the treatment. A treatment provider supplied three of the paper's authors. A foundation funded both the Stanford research and, separately, the veteran organisation helping create the participant pipeline. Another donor's family foundation supported the academic study before his separate nonprofit investment vehicle committed around $15 million to the biotech company that grew from it.

None of that proves the research is unsound.

It does mean that "who funded the study?" is probably the least interesting version of the question.

The bigger question is how an experimental treatment acquires enough scientific, financial and political momentum to become an institutionally serious idea.

First, what did the Stanford study actually show?

It is worth slowing down here, because the extraordinary numbers associated with the study have gradually become detached from its design.

The prespecified primary outcome was not PTSD remission, depression or suicidal ideation. It was change in functional disability, measured using the WHO Disability Assessment Schedule, from baseline to the immediate post-treatment assessment. That improvement was statistically significant, with a Cohen's d of 0.74 — meaningful, but not remotely the spectacular effect sizes that subsequently dominated coverage.

The enormous numbers came later in the hierarchy of outcomes.

At one month, functional disability had fallen further, producing an effect size of 2.20. PTSD produced d=2.54, depression d=2.80 and anxiety d=2.13. Response rates were above 93% and remission rates above 83% among the participants included in those analyses. The suicidal-ideation result was explicitly exploratory.

Those are extraordinary signals. They are not the same thing as extraordinary proof.

The study had no placebo group and no untreated comparison group. Participants were self-selected veterans who had already decided to pursue an unconventional psychedelic treatment in another country. They knew what they were receiving. The treatment occurred within a wider programme that included preparation and post-treatment coaching arranged through Veterans Exploring Treatment Solutions, or VETS, along with complementary activities available at the Mexican treatment centre. The authors themselves concluded that controlled clinical trials were needed to validate the findings.

This distinction matters because something interesting happened as the result travelled.

The paper said: very promising observational signal requiring controlled validation.

The political story increasingly became: Stanford showed that ibogaine produces extraordinary remission.

During the May 2025 Texas House debate, one representative described the Stanford participants as having an approximately 88% remission rate and told legislators that their PTSD symptoms were gone. Another described meeting Nolan Williams and veterans personally and repeated figures above 85%. The official legislative record shows the study functioning not merely as background evidence, but as a central argument for committing tens of millions of public dollars.

That transition — from exploratory finding to political fact — may be one of the most important parts of this story.

The people around the study

The funding statement in the Nature Medicine paper initially appears reassuringly simple.

Stanford states that it received no funding from VETS or Ambio, the Mexican treatment provider. Steve and Genevieve Jurvetson and the Sergey Brin Family Foundation independently supported the Stanford component, and the funders had no role in study design, execution, analysis or preparation of the manuscript.

All of that is true.

But "independently" should not be mistaken for "existing in completely separate worlds."

VETS facilitated recruitment for the study. Its role extended beyond simply advertising for volunteers: VETS paired participants with therapists familiar with ibogaine for structured preparation and post-treatment coaching, while participants independently travelled to Ambio in Mexico for treatment.

The Jurvetsons were separately major supporters of VETS. In its 2022 annual report, VETS placed the Jurvetson Family in its $250,000–$499,999 category for special gifts and pledges.

So Stanford was correct that it did not take VETS money. But one philanthropic household was supporting both Stanford's assessment research and an organisation involved in facilitating the participant pathway around that research.

That is not evidence of misconduct. It is evidence of an ecosystem.

Private philanthropy does not necessarily need to tell researchers what answer to produce. It can finance the veteran organisation, the academic laboratory, the conferences and advocacy infrastructure around a field while each remains legally and operationally distinct.

That form of influence is more subtle than sponsorship and potentially much more consequential.

Ambio was not outside the paper either

There is a similar complication around the treatment provider.

Stanford received no funding from Ambio, but three authors of the Nature Medicine paper — Jose Inzunza, Trevor Millar and Jonathan Dickinson — were affiliated with Ambio Life Sciences. According to the paper's author-contribution statement, they coordinated logistics at Ambio, supervised ibogaine treatment and monitoring, and reviewed the manuscript.

The paper disclosed their competing interests clearly. All three were shareholders in Ambio, which offers ibogaine treatment, and all three were inventors on a provisional patent involving adjunctive treatment intended to improve ibogaine safety. Dickinson was also the founder of Terragnosis, a company involved in sourcing ibogaine precursors and converting them semisynthetically into ibogaine.

Again, disclosure is precisely what scientific journals require when such relationships exist. A conflict of interest is not evidence that a result is false.

But it changes the picture.

This was not an entirely external academic team observing an unrelated clinic from afar. The treatment provider was represented within the author group, while Stanford researchers themselves were already developing intellectual property connected to magnesium-assisted ibogaine.

And that leads to Soneira.

The company was closer to the study than it first appears

When Google co-founder Sergey Brin's involvement with ibogaine became widely reported in July 2024, the story sounded like a familiar progression.

First, the Sergey Brin Family Foundation helped fund promising Stanford research.

Then Brin's separate nonprofit investment vehicle, Catalyst4, committed approximately $15 million of a $25 million financing round for Soneira, a biotechnology company attempting to develop ibogaine into a regulated treatment.

That description is accurate, but the relationship between the academic study and the company is tighter than a simple "research happens, investor notices research" sequence.

Soneira now says so itself.

Its website describes Nolan Williams' Stanford ibogaine research as the genesis of Soneira Inc., PBC. Williams subsequently served as an adviser to the company.

More revealingly, the intellectual-property timeline begins before the Nature Medicine paper was published.

A US patent titled Methods of treatment with an iboga alkaloid, now assigned jointly to Stanford and Soneira, claims priority to a provisional application filed on 14 September 2022, with further provisional filings in November 2022 and February 2023. The original Stanford cohort completed baseline and post-treatment assessments between November 2021 and September 2022.

In other words, the first patent priority date falls essentially at the end of the observational treatment cohort — more than a year before the paper appeared in January 2024.

The original publication disclosed relevant patent applications involving Williams, Ian Kratter and John Coetzee. What became clearer later was the relationship with Soneira itself.

The newly published 12-month MISTIC follow-up, released on 12 August 2026, provides a particularly useful snapshot. It states that Williams had served as a paid scientific adviser to Soneira and held equity or stock options in the company. Kratter is listed as receiving a salary from Soneira and holding equity or stock options. Williams, Kratter, Andrew Geoly and Coetzee are also named in connection with Stanford-owned magnesium-ibogaine intellectual property.

Williams died in October 2025 at the age of 43. The significance here is historical rather than personal: the disclosure record establishes how closely academic investigation and subsequent commercial development had become connected.

Soneira's current lead programme, SON-001, is a patent-pending ibogaine formulation administered with a cardiac-protective agent, aimed primarily at disability associated with traumatic brain injury.

That is strikingly close to the therapeutic concept examined by MISTIC.

So the pathway is not:

philanthropists → independent study → unrelated biotech notices study.

It is closer to:

philanthropy → veteran treatment network → Stanford observational research → academic IP → company formation → researcher/company relationships → major nonprofit investment.

Each step can be entirely legitimate while the overall structure remains worth understanding.

Sergey Brin is not primarily a psychedelic philanthropist

Brin's involvement also makes more sense when viewed against the scale of his neuroscience philanthropy.

The Stanford ibogaine grant is a small piece of an extraordinary biomedical funding operation. Forbes reported in 2025 that Brin had already spent roughly $1.75 billion on Parkinson's research, alongside major programmes in bipolar disorder and autism, with nearly $900 million in philanthropic grants during 2024 alone. His publicly reported lifetime charitable giving was then around $3.9 billion.

This is important because Brin's interest in ibogaine is sometimes presented as another example of Silicon Valley discovering psychedelics.

There is a better explanation available.

Brin has spent years constructing an infrastructure for unusually high-risk neuroscience research and translation. The central idea is not simply to fund university science and hope someone eventually commercialises it. His team has explicitly described wanting a feedback loop between basic research, clinical work, trial design, therapeutics and drug development.

Catalyst4 is built for precisely that.

It is not a conventional private foundation. It is a 501(c)(4) nonprofit, seeded by Brin in late 2021 with hundreds of millions of dollars in Alphabet and Tesla stock. Unlike a traditional charitable foundation, that structure can own entire for-profit companies and has considerably greater latitude to engage in lobbying. By May 2025, Forbes reported that Brin had transferred at least $1.5 billion into Catalyst4 and that it had already invested more than $600 million across startups and venture funds.

There is no evidence that Catalyst4 itself lobbied Texas or Arizona specifically for ibogaine legislation, and it would be wrong to imply that it did.

But its structure matters. Brin has built an organisation capable of operating simultaneously around science, investment, drug development and public policy rather than confining his activity to conventional charitable grants.

Soneira fits unusually well inside that model.

The Jurvetsons are doing something different

Steve and Genevieve Jurvetson have approached psychedelics much more broadly.

Genevieve has described entering the field while searching for options for family members dealing with opioid dependence and treatment-resistant depression. She subsequently became one of the most embedded philanthropic figures in the psychedelic field, serving on the board of the Psychedelic Science Funders Collaborative and chairing its Founders Circle.

Steve has described psychedelic science as a major philanthropic priority for the couple.

Their best-known public contribution remains the $2.6 million they gave towards MAPS' 2020 Capstone Campaign to complete the MDMA development programme for PTSD.

Trying to calculate their total psychedelic giving from public disclosures, however, creates a false precision. Some grants are disclosed, some are reported only in donor ranges, and others have no public figure at all. Bloomberg was reported in 2021 as saying that Steve Jurvetson intended to devote around half of his net worth to psychedelic science. Whether that intention ultimately translates into that scale of giving is another matter, but it makes a tally assembled from a few disclosed grants obviously misleading as an estimate of their total commitment.

What can safely be said is that several million dollars of Jurvetson psychedelic philanthropy is publicly identifiable, and that is clearly only part of the actual picture.

More important is where they sit institutionally.

The Jurvetsons support psychedelic research, veteran access organisations and broader movement infrastructure. Genevieve sits inside PSFC, itself designed to coordinate major donors around strategic opportunities in psychedelic science.

This terrain has already attracted critical scrutiny.

In 2025, Psymposia published its multi-part Psychedelic Syndicate investigation, portraying PSFC and associated donors as an elite network exercising excessive influence over the emerging psychedelic industry. A related critique subsequently appeared through Truthdig.

"Capture" is a stronger conclusion than the available evidence requires.

The more defensible observation is also the more interesting one: the same relatively small network of donors and organisations appears repeatedly across research, veteran advocacy, policy discussions, nonprofit institutions and commercial development.

One previously reported connection becomes particularly significant when the ibogaine story reaches Texas.

Rick Perry was already inside the psychedelic funding network

According to Psymposia's investigation, which cites internal PSFC emails, the Jurvetsons hosted a private PSFC gathering at their Half Moon Bay home on 14–16 May 2021 to launch the collaborative's Landscape Report. Guests reportedly included former Texas governor Rick Perry and California state senator Scott Wiener.

The same material described the Jurvetsons as major supporters of VETS.

That does not establish that a private gathering in California caused legislation in Texas four years later. There were many other important actors, particularly veterans themselves and advocates including Marcus and Amber Capone.

But it establishes something more modest and useful: the relationships predated the statute.

By 2025, Perry had become one of the most important political advocates for the Texas ibogaine initiative. When Texas approved the $50 million programme, Bryan Hubbard of the American Ibogaine Initiative told the Texas Tribune, "None of this is possible without Perry."

The chain therefore stretches back further than the Stanford publication.

Veteran psychedelic organisations were building relationships with wealthy psychedelic funders and political figures years before MISTIC appeared. Stanford then provided peer-reviewed evidence that could transform powerful testimonials into something legislators could describe as scientific validation.

That combination proved potent.

The study enters the legislature

The Texas House record is unusually revealing because it shows scientific evidence being translated into political language in real time.

During debate over Senate Bill 2308 in May 2025, Representative Cody Harris explicitly urged colleagues to "look at the Stanford study" and presented an approximately 88% veteran success figure. Representative Steve Toth Olcott described meeting veterans and speaking directly with Nolan Williams at an advocacy event.

The nuances of the original paper largely disappeared.

The modest d=0.74 prespecified primary outcome was not the memorable number. Neither was the absence of a control group.

What travelled were the dramatic remission figures.

That is not necessarily unusual. Policymakers rarely debate statistical analysis plans on the floor of a legislature. But here it had material consequences.

Texas enacted SB 2308 in June 2025 and committed $50 million in public money towards FDA-oriented ibogaine development. The structure went beyond a conventional academic research grant. Prospective private partners were expected to match the state's investment, establish a Texas presence and provide the state with at least 20% of future commercial revenue arising from a successful drug programme, with part of the state's return reserved for veterans.

Texas was effectively attempting to act not only as research funder but as a participant in pharmaceutical development.

Then reality complicated the plan.

By March 2026, state leaders said multiple drug-company proposals had failed to meet the programme's requirements. Texas announced that it intended to move ahead with its own research effort, although analysts noted that the existing legislation required a private match and industry participation, potentially creating legal and structural problems for that approach.

Even that difficulty demonstrates how far ibogaine had travelled.

A compound that US veterans had been crossing the border to obtain in private Mexican clinics was now the subject of a state-level attempt to build an FDA drug-development programme using $50 million in taxpayer capital.

And now Arizona

Arizona has followed on a smaller but still significant scale.

Its FY2026 legislation appropriated $5 million for a certified clinical study of ibogaine in neurological conditions including TBI and PTSD. The recipient was required to demonstrate at least another $5 million in committed private funding.

On 5 August 2026, Barrow Neurological Institute announced that the Arizona Department of Health Services had awarded it the $5 million grant for a Phase 1/2 clinical trial of ibogaine in neurological disorders including TBI. Barrow plans to use a synthesized form of ibogaine and expects its first participant in 2027.

That is much closer to the type of controlled prospective clinical development needed to answer questions the Stanford observational study could not.

So the sequence has effectively become:

private treatment → private veteran support → philanthropically funded observational study → spectacular secondary outcomes → peer-reviewed publication → advocacy and legislative testimony → private biotech capital → public research appropriations → formal clinical development.

The philanthropy was the beginning, not the end.

The Stanford cohort has now reached twelve months

There is another development that arrived only days ago.

On 12 August 2026, the Stanford group published its 12-month follow-up of the original MISTIC cohort in Translational Psychiatry. Twenty-five of the original 30 participants completed the one-year assessment. Improvements remained large, and among participants who had achieved remission immediately after treatment, the estimated probability of sustained remission at twelve months was 84% for PTSD, 66% for depression and 61% for anxiety.

Again, those are remarkable observations.

Again, causal interpretation is difficult.

Most participants reported using other psychedelics or pursuing additional interventions during the follow-up period. The authors explicitly warn that this complicates any attempt to attribute the long-term trajectory to the original ibogaine treatment alone and again call for randomized controlled research.

It is an almost perfect illustration of the difference between a compelling signal and a settled treatment effect.

The signal has become stronger.

The need for proper controls has not disappeared.

Then there is the question of where the ibogaine came from

There is one final thread that changes the story again.

Ibogaine is routinely described as deriving from Tabernanthe iboga, the Central African plant inseparable from Bwiti traditions in Gabon and neighbouring countries.

But that is not where the ibogaine used in the Stanford cohort came from.

The Nature Medicine methods state that the ibogaine hydrochloride was synthesized in South Africa using voacangine sourced from Voacanga africana.

That distinction matters.

Voacanga africana is another African plant containing iboga alkaloid precursors. Converting voacangine semisynthetically into ibogaine allows pharmaceutical production without harvesting Tabernanthe iboga root bark in Gabon. Fully synthetic routes can detach production from either plant still further.

From a conservation perspective, that can be an advantage. Commercial pressure on wild iboga has long generated concerns about sustainability and supply.

From an access-and-benefit-sharing perspective, however, things become more complicated rather than simply disappearing.

Using Voacanga instead of Gabonese Tabernanthe iboga may remove some direct questions about access to Gabonese biological material, but it does not automatically remove Nagoya Protocol or wider ABS considerations. Those depend on the actual country from which the genetic resource was obtained, domestic access legislation, the date and circumstances of access, the use of associated traditional knowledge and any mutually agreed terms.

South Africa itself is a Party to the Nagoya Protocol.

So the appropriate question is not whether synthetic or semisynthetic ibogaine magically escapes benefit sharing. It is: which resources and knowledge entered the development pathway, under which jurisdiction, and what benefit-sharing arrangements followed them?

There is also a broader ethical question that legal ABS rules do not completely answer.

A pharmaceutical product can become progressively detached from the African plant supply chain while continuing to derive its scientific and cultural significance from a drug whose history of human use exists because African communities preserved knowledge of iboga.

Soneira appears aware of that tension.

As a public benefit corporation, it has established a programme called Healing Forward. Giving Back, saying it recognises the traditional knowledge and cultural significance of iboga alkaloids and intends to support Indigenous communities and conservation. Its current charter says that once profitable it will contribute 1% of annual net profits as direct financial assistance while continuing other partnerships.

That is more concrete than vague language about "honouring Indigenous wisdom."

It is still different from a formal Nagoya benefit-sharing agreement tied to access to a particular genetic resource or body of traditional knowledge.

And that distinction is going to become increasingly important if synthetic ibogaine becomes a valuable regulated medicine.

The route around Gabon

This may ultimately be the strangest transformation in the entire story.

A molecule became known to Western medicine because of an African psychoactive plant and because communities in Central Africa maintained sophisticated traditions around its use.

The contemporary clinical pathway then moved through veteran networks in the United States, private treatment centres in Mexico, Voacanga-derived precursor chemistry in South Africa, assessments at Stanford, patents, Silicon Valley capital and American state legislatures.

The final pharmaceutical product may eventually be entirely synthetic.

At that point, the physical supply chain could contain no Gabonese iboga at all.

Yet the historical debt has not vanished merely because chemists can now make the molecule somewhere else.

That is precisely where questions about Nagoya, ABS and reciprocity become more interesting rather than less.

This is not a conspiracy story

There is an easy version of this article in which wealthy Silicon Valley donors secretly control psychedelic medicine.

The evidence does not justify it.

The Stanford paper disclosed funding and competing interests. Its funders were expressly excluded from study design, analysis and publication decisions. The limitations of the observational design were stated. The researchers repeatedly called for controlled trials. Soneira publicly identifies its commercial and public-benefit objectives. Texas debated and passed its programme through the normal legislative process.

There is no need to manufacture hidden control when the visible network is already interesting enough.

The better lesson is about agenda-setting.

Steve and Genevieve Jurvetson did not need to dictate a Stanford result to influence psychedelic science. Supporting Stanford, VETS, PSFC and other parts of the psychedelic ecosystem helps determine which neglected ideas acquire researchers, participants, institutions and credibility.

Sergey Brin did not need to turn an academic grant into a commercial instruction. His family foundation could support exploratory neuroscience while Catalyst4 separately supplied the type of risk-tolerant capital capable of turning promising research into drug development.

Veteran advocates did not need randomized trials before approaching lawmakers. They possessed compelling personal testimony, relationships, a peer-reviewed Stanford publication and a patient population with an obvious unmet need.

Politicians did not need to pretend the evidence was perfect. They could decide that the signal justified spending public money to obtain the evidence that did not yet exist.

That is how fields move.

The philanthropy was the smallest part

Looked at narrowly, the story began with an acknowledgement section.

Steve and Genevieve Jurvetson and the Sergey Brin Family Foundation funded the Stanford component of an unusual ibogaine study.

Looked at properly, that grant sits inside something much larger.

The Jurvetsons already occupied a network connecting psychedelic philanthropy, veteran organisations, PSFC and political advocates. VETS helped create the pathway through which the Stanford cohort reached treatment. Ambio delivered that treatment and had shareholders within the paper's author list. Stanford investigators developed intellectual property during the research period. Soneira says the study became the genesis of the company. Williams later advised Soneira and held equity; Kratter now receives a salary from it. Brin's Catalyst4 then committed around $15 million to Soneira.

Meanwhile, the Stanford findings left academia.

They appeared in advocacy events. They were repeated on the floor of the Texas House. Texas committed $50 million. Arizona committed another $5 million plus a private matching requirement. Barrow has now received that grant to perform an early-stage clinical trial.

And behind all of it sits an older question.

The molecule being moved towards an FDA pharmaceutical pathway carries a history extending far beyond Stanford, Silicon Valley or the US military. The material used in the famous study already came through a semisynthetic Voacanga route rather than Gabonese iboga, and future products may require no African plant material whatsoever.

The scientific pathway is becoming more sophisticated.

The financial pathway is becoming larger.

The biological supply chain is becoming easier to detach from the drug's geographical origins.

Whether the system develops an equally sophisticated way of recognising where the knowledge story began remains unresolved.

The original Stanford paper was a 30-person uncontrolled observational study.

Two and a half years later, its descendants include patents, a biotechnology company, billionaire investment, follow-up neuroscience, a $50 million Texas programme, a new Arizona clinical trial and legislation explicitly built around moving ibogaine towards FDA approval.

That does not mean the study proved ibogaine works.

It means it proved something else beyond doubt:

a sufficiently compelling scientific signal, placed inside the right network of people, money and institutions, can travel astonishingly far.